Myelodysplastic syndrome (MDS)/Myeloproliferative neoplasm (MPN) with loss of long arm of chromosome 5 (del 5q): Clinical case and treatment perspectives.

this clinical case report presents a patient diagnosed with a myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN), specifically myelofibrosis with a deletion of the long arm of chromosome 5 (del 5q), an exceedingly rare anomaly in chronic myeloproliferative disorders. We performed a thorough analysis of the patient’s clinical, laboratory, and molecular-genetic characteristics to evaluate their impact on prognosis, treatment decisions, and therapeutic outcomes. After excluding other genetic abnormalities, the patient was treated with lenalidomide and prednisolone, resulting in improved clinical and hematological parameters. These findings are consistent with previous studies and suggest the potential efficacy of lenalidomide in treating patients with MDS/MPN characterized by del 5q, especially when no additional genetic abnormalities are present.

Authors

Institutions

Publication Details

Journal
Ukrainian Scientific Medical Youth Journal
Published
2024-09-30
DOI
https://doi.org/10.32345/usmyj.3(149).2024.75-80
Primary Topic
Myeloproliferative Neoplasms: Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Myelodysplastic syndrome (MDS)/Myeloproliferative neoplasm (MPN) with loss of long arm of chromosome 5 (del 5q): Clinical case and treatment perspectives.

Oksana Karnabeda, Kateryna Khurdepa
Ukrainian Scientific Medical Youth Journal
Myeloproliferative Neoplasms: Diagnosis and Treatment
article

Myelodysplastic syndrome (MDS)/Myeloproliferative neoplasm (MPN) with loss of long arm of chromosome 5 (del 5q): Clinical case and treatment perspectives.

Oksana Karnabeda, Kateryna Khurdepa
article en

Abstract

this clinical case report presents a patient diagnosed with a myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN), specifically myelofibrosis with a deletion of the long arm of chromosome 5 (del 5q), an exceedingly rare anomaly in chronic myeloproliferative disorders. We performed a thorough analysis of the patient’s clinical, laboratory, and molecular-genetic characteristics to evaluate their impact on prognosis, treatment decisions, and therapeutic outcomes. After excluding other genetic abnormalities, the patient was treated with lenalidomide and prednisolone, resulting in improved clinical and hematological parameters. These findings are consistent with previous studies and suggest the potential efficacy of lenalidomide in treating patients with MDS/MPN characterized by del 5q, especially when no additional genetic abnormalities are present.

Ukrainian Scientific Medical Youth JournalVol. 149(3)
National Academy of Medical Sciences of Ukraine (UA), Bogomolets National Medical University (UA)
Openalex Percentile: Top 72%
Myeloproliferative Neoplasms: Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.